The Board at its meeting held on July 25, 2025 has approved amendment to the policy for determination of materiality of event
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences reported Q1 FY26 (quarter ended June 30, 2025) revenue from operations of Rs. 16,892 lakhs, up marginally from Rs. 16,542 lakhs in Q1 FY25. Profit before tax stood at Rs. 3,543 lakhs, nearly flat compared to Rs. 3,600 lakhs a year ago, with profit after tax at Rs. 2,629 lakhs versus Rs. 2,676 lakhs. The quarter included an exceptional gain of Rs. 10,990 lakhs from the assignment of surplus leasehold land at MIDC Navi Mumbai. Excluding this one-time item, underlying profits were slightly lower year-on-year. The Board also approved an amendment to the company's policy for determining materiality of events, in line with updated SEBI Listing Regulations. The statutory auditors (S R B C & Co LLP) issued an unqualified limited review report with no observations.
Core business performance was largely flat, but the large one-time land monetization gain will inflate reported earnings for the quarter. Excluding the exceptional item, the business shows no meaningful growth and slight margin pressure, which investors should keep in mind when valuing the stock. The policy revision is a routine regulatory compliance update and has no direct financial impact.